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Kawasaki disease (KD) is an acute febrile illness
characterized by mucosal inflammation, skin rash, and
cervical lymphadenopathy, and is observed most often in
children younger than 5 years of age [1–3]. KD is an acute
vasculitis syndrome of unknown etiology that primarily
affects small and medium-sized arteries, particularly the
coronary artery [4–9].
Standard treatment for KD is intravenous immu-
noglobulin (IVIG) and aspirin [10,11]. Administration of
high-dose IVIG reduces both the duration of fever and the
incidence of coronary artery aneurysms when given within
a few days after the onset of the disease [3]. None-
theless, approximately 10% of patients have persistent fever
despite treatment [3]. The aims of the present study were to
determine the rate of treatment failure of the first dose of
IVIG in our patients with KD and to determine the possible
predisposing factors, such as age and gender.
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The purpose of this study was to determine the initial rates of intravenous a-globulin treatment (IVIG) failure
in Kawasaki disease (KD) and their predisposing factors. This study was a retrospective analysis of the initial
response to IVIG (2 g/kg), assessed from the medical reports of all patients admitted to Namazee Hospital
pediatric ward, from March 1998 to March 2002, and who fulfilled the criteria for KD. Data were available
for 64 patients, 58 of whom (90.6%) became afebrile 48 hours after completion of the initial dose of IVIG
(Group I) and six (9.4%) who remained febrile (Group II). Two patients had a prompt response to a second
dose of IVIG. In Group I, five patients (8.6%) developed coronary artery disease, seen on echocardiography.
In Group II, two patients (33.3%) developed coronary artery disease. No significant difference was found in
the prevalence of coronary artery disease between the two groups (p = 0.12), or in age or gender. The rate of
initial treatment failure was 9.4% in this cohort of patients, which is comparable with previous reports. No
predictive factors such as coronary artery disease, age or gender were found for initial treatment failure in KD.
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PATIENTS AND METHODS
We reviewed the records of all patients who fulfilled the
criteria for diagnosis of KD [10]. They were treated with
IVIG (2 g/kg) and aspirin (80–100 mg/kg/day) at Namazee
Hospital, which is affiliated with Shiraz University of
Medical Sciences, during a 4-year period, from 1998 to 2002.
Information obtained from the medical records included
patient age, gender, and duration of illness at first treatment.
The first day of fever was assumed to be the first day of
illness. We routinely obtain an echocardiogram on the first
day of hospital admission, and echocardiography results
were used to assess clinical outcome. Treatment failure was
defined as persistent fever for at least 48 hours after completion
of the IVIG infusion. Patients were divided into two groups
according to the response 48 hours after completion of IVIG
administration: Group I included patients who became
afebrile by 48 hours, while Group II patients remained febrile.
Statistical analysis
Data compared between the two groups were gender, age,
duration of fever prior to IVIG treatment, and coronary
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artery disease. Data analysis was performed with Epi Info
2002 (Centers for Disease Control and Prevention, Atlanta,
GA, USA), Fisher’s exact test and SPSS version 11.5 (SPSS
Inc, Chicago, IL, USA).
RESULTS
The medical records of 64 patients were reviewed. All
patients received IVIG 2 g/kg in a single dose or two doses
on two consecutive days. Clinical data are shown in Table
1. The male to female ratio was 1.8:1 and ages ranged from
5 months to 12 years with a mean of 4 years (3.8 years in
males, 4.4 years in females).
Most patients (58, 90.6%) were afebrile 48 hours after
completion of the initial dose of IVIG infusion (Group I), but
six (9.4%) remained febrile (Group II) (Figure). Two patients
with initial treatment failure (33.3%) responded to a second
dose of IVIG. Gender distribution was similar in the two
groups (64% of Group I and 67% of Group II were male).
Patients in Group I were slightly older than those in Group
II (Table 1). Significantly more patients in Group II than
Group I were treated within 5 days of the start of fever
(p = 0.02) (Table 2).
In Group I, two patients (3.4%) had mild mitral
regurgitation at first echocardiography, one patient (1.7%)
showed mild mitral regurgitation, mild tricuspid regur-
gitation, and minimal pericardial effusion, and five pa-
tients (8.6%) showed coronary abnormalities (3 developed
dilatation of coronary arteries and 2 developed coronary
artery aneurysm) (Table 3). In Group II, first echo-
cardiography was normal in four patients, one of whom
developed coronary artery aneurysm after 2 weeks. Of the
other two patients, one (16.7%) showed mild tricuspid
regurgitation and mitral regurgitation, and one (16.7%)
showed dilated coronary arteries. Therefore, two patients
in Group II had coronary lesions.
DISCUSSION
Namazee Hospital is a referral center for Fars Province
(population, 3 million) in South Iran, where hospital
pediatricians are familiar with the diagnosis and treatment
of KD. In 2001, Sadeghi et al reported the demographic
features and clinical manifestations of KD in Iran [12].Figure. Treatment response in 64 patients with Kawasaki disease.
Table 1. Clinical data of 64 patients with Kawasaki disease
Group I (n = 58) Group II (n = 6) p
Gender  1
Male 37 4
Female 21 2
Age
Mean (mo) 50.7 ± 34.8 28.8 ± 27.9 0.142
< 1 yr 2 (3.4%) 1 (16.7%)
1–5 yr 41 (70.7%) 4 (66.7%)
> 5 yr 15 (25.9%) 1 (16.7%)
Mean body weight (kg) 16.1 ± 6.1 11.9 ± 4.1 0.105
Mean duration of fever after first dose of IVIG (d) 1.3 ± 0.48 5.6 ± 1.86 0.002*
Number of coronary lesions 5 2 0.12
Group I: responsive to initial intravenous immunoglobulin treatment; Group II: not responsive to initial intravenous immunoglobulin treatment;
IVIG = intravenous a-globulin treatment. *p < 0.05.
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Treatment failure in the present study was 9.4%,
comparable to results from other studies, which range from
13.2% to 23% [3,13,14]. Among patients who failed initial
treatment (Group II), two (33.3%) received a second dose of
IVIG. The US/Canadian Kawasaki Syndrome Study Group
found that the rate of retreatment for persistent or recurrent
fever varied among participating centers (25–100%) [13].
Retreatment with a third or further dose (2 g/kg) has also
been reported [15].
There was no significant difference between the groups
in the prevalence of coronary artery disease (5/58 vs 2/6;
p = 0.12). Hashino et al found an overall prevalence of
coronary artery lesions of 6.5%, which rose to 48.6% in the
treatment failure group [3], while Burns et al reported
prevalences of 11% and 24%, respectively [13]. Our results
are similar to those of Durongpisitkul et al [16].
The severity of clinical manifestions of KD that lead to
retreatment with IVIG or using a second line of treatment
such as steroid, cyclophosphamide or infliximab varies
[15–17]. This may reflect different genetic susceptibility.
Gender, age and weight were not predictors of treatment
failure in KD (Table 1), which supports previous findings
[14,16].
Two recent reports of the efficacy of early treatment of
KD (< 5 days after fever onset) found that early treatment
resulted in persistent fever [18,19] and more frequent
retreatment with IVIG [19]. This is in agreement with our
results, where three of the six patients in the treatment
failure group received their initial IVIG on or before day 5,
significantly more so than in Group I (5/58; p = 0.02) (Table
2). It is recommended that, to prevent coronary artery
disease, KD be treated before day 10 of illness [11]. This
treatment strategy tends towards treating as soon as
possible, but it is not documented if early treatment (before
day 5) is associated with fewer complications and lower
morbidity.
We conclude that initial treatment failure is not
uncommon in KD, although it is not associated with early
coronary artery disease. The long-term prognosis after
initial treatment failure should be evaluated in future
studies.
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